Marksans Pharma share news, announcements and annual reports
NSE: MARKSANSBSE: 524404Pharmaceuticals & BiotechnologySmall Cap
Marksans Pharma Limited · Formerly Tasc Pharmaceuticals · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 1994 on BSE, Jan 2002 on NSE
Last close ₹306.20down ₹9.15 (2.90%)BSE ₹306.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹315.35.
30 Oct: open ₹317.00, high ₹317.35, low ₹304.90
52-week range of traded prices to 30 Oct 2026
₹155.00Low, 30 Mar 2026₹350.95High, 24 Sep 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹13,876 Cr592nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 26.85
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.59
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record.
- 17.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 19.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 12,10,63344.3% delivered
Marksans Pharma share news and announcements
683 announcements, routine notices left out, newest first. Page 11 of 14.
Jan 2016
13 Jan · News Verification
News about Marksans Pharma Limited. The media had reports that "Marksans Pharma's Goa Plant gets notification of deficiency in GMP from UK MHRA, 40% of Marksans Pharma's revenue comes from UK". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Marksans Pharma Limited has vide its letter inter-alia stated, "UK MHRA has conducted a GMP inspection of the Company's plant at Goa in the month of November 2015. Pursuant to the inspection, UK MHRA has issued certain observations which Company has responded to. The Company is awaiting further response from UK MHRA in this matter as on date. Company's Goa plant is functioning normally and the shipments to UK is continuing in the normal course of business."13 Jan · News Verification
Exchange has sought clarification from Marksans Pharma Limited, with respect to recent news item captioned "Marksans Pharma's Goa Plant gets notification of deficiency in GMP from UK MHRA, 40% of Marksans Pharma's revenue comes from UK". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Dec 2015
Nov 2015
10 Nov · Business
Oct 2015
1 Oct · Disclosure of Voting Pattern - Clause 35A
Sep 2015
14 Sep · Updates
Aug 2015
Jul 2015
Jun 2015
9 Jun · Code of Conduct under SEBI(PIT) Reg., 2015
May 2015
Apr 2015
Mar 2015
Feb 2015
Jan 2015
29 Jan · Board meeting
Inter alia to consider and approve Unaudited Financial Results for the Quarter ended 31st December, 2014.
Oct 2014
20 Oct · Board meeting
Inter alia, to consider and approve Unaudited Financial Results of the Company for the Quarter ended September 30, 2014.10 Oct · Address Change
Effective from October 10, 2014, the Company's Registered Office has changed to the following new address:11th floor, "GRANDEUR", Opp. Gundeecha Symphony, Veera Desai Extention Road, Oshiwara, Andheri (W), Mumbai-400 053. Telephone: +91 22 4001 2000, Telefax: +91 224001 2011E-mail: companysecretary@marksanspharma.com
Sep 2014
29 Sep · Disclosure of Voting Pattern - Clause 35A
Aug 2014
28 Aug · Updates
Company is providing e-voting facility to its shareholders, in respect of all shareholder's resolutions, to be passed at Annual General Meeting. The e voting period will start on September 18, 2014 at 10:00 am and will end on September 20, 2014 at 06:00 pm.28 Aug · Dividend
Dividend, if declared at the Annual General Meeting to be held on September 25, 2014 will be paid on or after October 06, 2014.28 Aug · Meeting
Register of Members and Share Transfer Books of the Company shall remain closed from September 20, 2014 to September 25, 2014 (Both days inclusive) for the purpose of Annual General Meeting to be held on September 25, 2014 and payment of Dividend .
Jul 2014
30 Jul · Address Change
Due to a massive fire that broke out in the building Lotus Business Park wherein the company has its registered office, the company has made alternative arrangement to carry out the day to day affairs on a temporary basis from a different premises at Suit No. 8, Tower 3, Equinox Business Park, Off Bandra Kurla Complex, L.B.S. Marg, Mumbai - 400070. The said new address for all correspondence to the Company on a temporary basis untill further intimation.
May 2014
29 May · Results
29 May · Dividend
Board of Directors of the Company at its meeting held on May 29, 2014 has recommended dividend of 10% which is Re. 0.10 per equity share of Re. 1/- each face value subject to the approval of shareholders in the ensuing Annual General Meeting.29 May · Results